Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314662 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,778
- Enrollment target
NCT03314662: Completed Phase 3 study, sponsored by Seqirus.
NCT03314662 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 1,778 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03314662, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,778 participants
- Enrollment target
Study Summary
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Primary Outcome
The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.
Interventions
- BIOLOGICAL MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- BIOLOGICAL Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
- BIOLOGICAL MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,778 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 3 |
What the finished NCT03314662 record still lists
NCT03314662 is an interventional study that assigns participants to a tested intervention. Its 1,778 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 3 interventions - of which MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) is the first listed.
NCT03314662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03314662 about?
NCT03314662 is a clinical study titled "Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults". This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B stra...
What is the current status of trial NCT03314662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,778 participants. The study started on 2017-10-17. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT03314662?
The interventions under investigation include: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) (BIOLOGICAL), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) (BIOLOGICAL), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03314662?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03314662's enrollment target sits among peer trials
1,778 126th of 2000 higher than 1,875 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI